Clinical trials: Relapsed
B-cell Non-Hodgkin Lymphoma
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-cell non-hodgkin lymphoma.
- Trial name
- GLOFTST (NCT06497452)
- Testing
- Glofitamab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
B-cell Non Hodgkin Lymphoma
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
To study the safety and effectiveness of cord blood-derived CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma
- Trial name
- NCT05472558
- Testing
- anti-CD19 CAR-NK
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Relapsed or Refractory Solid Tumors
A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)
The main purpose of this study is to evaluate the antitumor activity and safety of lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration.
- Trial name
- E7080-G000-231 (NCT04447755)
- Testing
- Lenvatinib
- Where
- 49 sites in United States, Argentina and 18 more
- Volunteers
- 127 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Sclerosis
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing…
- Trial name
- BRAVO (NCT00605215)
- Testing
- Laquinimod, Avonex®
- Where
- 170 sites in United States, Bulgaria and 17 more
- Volunteers
- 1,331 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
This phase II trial studies how well vorinostat and combination chemotherapy before donor stem cell transplantation work in treating patients with aggressive B-cell or T-cell non-Hodgkin lymphoma that has come back (relapsed).
- Conditions
- Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04220008
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine
- Sponsor
- M.D. Anderson Cancer Center
Smoking Cessation
The Long-Term Quitting (Smoking Cessation) Study
Relapse after a serious quit attempt occurs in 70-90% of smokers who try to quit smoking. This study utilizes a sequential, multiple assignment, randomized trial (SMART) design - - an innovative multi-phase approach - - to test…
- Trial name
- NCT02564315
- Testing
- Nicotine Mini-Lozenge for 11 Months, Preparation Phase Behavioral Reduction Counseling, Preparation Phase Recycling Counseling
- Where
- United States
- Volunteers
- 1,154 people
- Sponsor
- University of Wisconsin, Madison
Relapsing-remitting Multiple Sclerosis, RRMS
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with…
- Trial name
- NCT01051817
- Testing
- AIN457
- Where
- 16 sites in Czechia, Russia and 1 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Central Nervous System Inflammation, MOG-IgG Associated Disease
Azathioprine in MOGAD
MOG-IgG associated disease (MOGAD) is a rare inflammatory disease of the central nervous system recently described. Initially reported as monophasic, data from incident cohorts suggests that around 50% of adult patients with…
- Trial name
- MOGwAI (NCT05349006)
- Testing
- Azathioprine
- Where
- 17 sites in France
- Volunteers
- 126 people
- Sponsor
- Hospices Civils de Lyon
Lymphoma, Follicular
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
- Trial name
- NCT05228158
- Testing
- Tazemetostat
- Where
- 135 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumors
A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)
The study determined the recommended Phase 2 loading and maintenance doses and dose schedules for administering dalotuzumab using dose-limiting toxicities (DLTs) observed during the entire treatment period (Up to 18 months).
- Trial name
- NCT00635778
- Testing
- dalotuzumab
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis Relapse
Evaluation of Relapse Presence in Multiple Sclerosis
Purpose: This study aims to investigate the demonstrability of increased inflammation and neurodegeneration in multiple sclerosis (MS) patients in relapse period compared to MS patients in remission by cross-sectional analysis of…
- Trial name
- NCT05218317
- Testing
- in-vivo Corneal Confocal Microscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Marmara University
Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
- Trial name
- ALT-101 (NCT07586618)
- Testing
- 4A10
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Allterum Therapeutics, Inc
AML
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
Longterm disease-free survival (DFS) of older patients with acute myeloid leukemia (AML) remains poor. The vast majority of AML patients relapses within two years after start of therapy1,2.
- Trial name
- TCP-AML (NCT02261779)
- Testing
- Tranylcypromine, Tretinoin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Tuberculosis, Pulmonary, Undernutrition
The INSTITUT Study Tuberculosis Nutritional Support
Undernutrition is a leading global risk factor of tuberculosis (TB) and a prevalent comorbidity associated with TB. In Benin, the National TB Program systematically provides nutritional support to all persons with TB (PWTB)…
- Trial name
- INSTITUT (NCT06084715)
- Testing
- Nutritional support
- Where
- 2 sites in Benin, Togo
- Volunteers
- 769 people
- Sponsor
- Boston Medical Center
Smoking
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit.
- Trial name
- RENEW-Smk-1 (NCT07223840)
- Testing
- Brenipatide
- Where
- 29 sites in United States, China and 1 more
- Volunteers
- 222 people
- Sponsor
- Eli Lilly and Company
Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
The first part of the study is to evaluate and determine if three different forms of MGCD0103 (free base FB-MGCD0103, tartaric acid free base [TA-FB-MGCD0103], and dihydrobromide [2HBr] salt formulation MGCD0103) have the same…
- Trial name
- NCT00543582
- Testing
- MGCD0103 and Azacitidine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Mirati Therapeutics Inc.
Multiple Myeloma
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment…
- Trial name
- NCT02612779
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 22 sites in United States
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
CRC (Colorectal Cancer)
Study of Ruxolitinib in Colorectal Cancer Patients
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
- Trial name
- NCT02119676
- Testing
- Ruxolitinib, Regorafenib
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 396 people
- Sponsor
- Incyte Corporation
Hodgkin Lymphoma
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
This study is being done to test the safety and effectiveness of pembrolizumab followed by radiation therapy in Hodgkin lymphoma.
- Trial name
- NCT03179917
- Testing
- Pembrolizumab, Involved Site Radiation Therapy
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Sclerosis
Preventive Use of COrticosteroids During the Post-Partum in Relapsing MS Patients (COPP-MS)
Multiple Sclerosis (MS) is most prevalent among women of childbearing age. The post-partum (PP) period is a critical phase in MS patients, during which a recrudescence of disease activity is expected.
- Trial name
- COPP-MS (NCT03917589)
- Where
- 5 sites in France
- Volunteers
- 350 people
- Sponsor
- Rennes University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.